Private Trust Co. NA reduced its position in Stryker Co. (NYSE:SYK) by 0.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,345 shares of the medical technology company’s stock after selling 124 shares during the quarter. Stryker makes up approximately 0.8% of Private Trust Co. NA’s portfolio, making the stock its 27th biggest position. Private Trust Co. NA’s holdings in Stryker were worth $3,623,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in SYK. Oregon Public Employees Retirement Fund lifted its stake in Stryker by 8,029.5% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 6,075,473 shares of the medical technology company’s stock worth $39,000 after purchasing an additional 6,000,739 shares during the last quarter. Capital International Investors purchased a new stake in Stryker during the third quarter worth approximately $831,822,000. Norges Bank purchased a new stake in Stryker during the fourth quarter worth approximately $474,132,000. Capital World Investors increased its position in Stryker by 987.2% during the third quarter. Capital World Investors now owns 1,657,979 shares of the medical technology company’s stock worth $294,590,000 after buying an additional 1,505,479 shares during the period. Finally, BlackRock Inc. increased its position in Stryker by 4.1% during the fourth quarter. BlackRock Inc. now owns 24,882,912 shares of the medical technology company’s stock worth $3,900,399,000 after buying an additional 975,678 shares during the period. 74.61% of the stock is owned by institutional investors.
NYSE SYK opened at $185.04 on Thursday. Stryker Co. has a twelve month low of $144.75 and a twelve month high of $199.85. The stock has a market cap of $67.26 billion, a P/E ratio of 25.31, a price-to-earnings-growth ratio of 2.19 and a beta of 0.88. The company has a current ratio of 2.02, a quick ratio of 1.41 and a debt-to-equity ratio of 0.72.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be paid a dividend of $0.52 per share. The ex-dividend date of this dividend is Thursday, March 28th. This represents a $2.08 annualized dividend and a yield of 1.12%. Stryker’s dividend payout ratio is presently 28.45%.
In other news, VP Katherine Ann Owen sold 29,247 shares of the stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $185.62, for a total value of $5,428,828.14. Following the completion of the sale, the vice president now owns 11,131 shares in the company, valued at $2,066,136.22. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP M Kathryn Fink sold 180 shares of the stock in a transaction dated Monday, February 4th. The shares were sold at an average price of $176.77, for a total value of $31,818.60. The disclosure for this sale can be found here. Insiders have sold 130,455 shares of company stock valued at $24,723,292 over the last 90 days. 7.20% of the stock is currently owned by insiders.
Several research analysts have commented on SYK shares. BTIG Research lifted their price target on Stryker to $211.00 and gave the stock a “buy” rating in a research report on Monday, March 18th. Evercore ISI raised Stryker from an “in-line” rating to an “outperform” rating and set a $156.75 target price on the stock in a report on Wednesday, January 2nd. Piper Jaffray Companies reissued an “overweight” rating and issued a $205.00 target price on shares of Stryker in a report on Friday, March 1st. Morgan Stanley dropped their target price on Stryker from $212.00 to $197.00 and set an “overweight” rating on the stock in a report on Wednesday, January 2nd. Finally, SunTrust Banks boosted their target price on Stryker to $205.00 and gave the company a “positive” rating in a report on Monday, February 4th. Eight equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $195.99.
ILLEGAL ACTIVITY WARNING: This news story was originally published by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://www.baseballdailydigest.com/news/2019/04/25/stryker-co-syk-holdings-trimmed-by-private-trust-co-na.html.
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Further Reading: Day Trading
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.